|
1
|
Kawanaka M, Watari J, Kamiya N, Yamasaki
T, Kondo T, Toyoshima F, Ikehara H, Tomita T, Oshima T, Fukui H, et
al: Effects of Helicobacter pylori eradication on the development
of metachronous gastric cancer after endoscopic treatment: Analysis
of molecular alterations by a randomised controlled trial. Br J
Cancer. 114:21–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen J, Cheng L, Xie Z and Li Z: Impact of
preoperative oral liquid carbohydrate on postoperative insulin
resistance in gastric cancer patients and its associated study.
Zhonghua Wei Chang Wai Ke Za Zhi. 18:1256–1260. 2015.(In Chinese).
PubMed/NCBI
|
|
3
|
Park SR, Hong YS, Lim HS, Seong MW, Kong
SY, Kim SY, Park YI and Jung KH: Phase I clinical and
pharmacokinetic/pharmacogenetic study of a triplet regimen of
S-1/irinotecan/oxaliplatin in patients with metastatic colorectal
or gastric cancer. Cancer Chemother Pharmacol. 72:953–964. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li NA, Wang W, Xu B and Gong H: miR-196b
regulates gastric cancer cell proliferation and invasion via
PI3K/AKT/mTOR signaling pathway. Oncol Lett. 11:1745–1749. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X,
Wang D, Yang T, Pan SY, Chen XW and Zhou SF: Danusertib, a potent
pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle
arrest and programmed cell death and inhibits epithelial to
mesenchymal transition involving the PI3K/Akt/mTOR-mediated
signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Drug Des Devel Ther. 9:1293–1318. 2015.PubMed/NCBI
|
|
6
|
Riquelme I, Tapia O, Espinoza JA, Leal P,
Buchegger K, Sandoval A, Bizama C, Araya JC, Peek RM and Roa JC:
The gene expression status of the PI3K/AKT/mTOR pathway in gastric
cancer tissues and cell lines. Pathol Oncol Res. 22:797–805. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang B, Yang Y, Shi X, Liao W, Chen M,
Cheng AS, Yan H, Fang C, Zhang S, Xu G, et al: Proton pump
inhibitor pantoprazole abrogates adriamycin-resistant gastric
cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin
signaling and epithelial-mesenchymal transition. Cancer Lett.
356:704–712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo H, Cui H, Peng X, Fang J, Zuo Z and
Deng J, Wang X, Wu B, Chen K and Deng J: Modulation of the PI3K/Akt
pathway and Bcl-2 family proteins involved in chicken's tubular
apoptosis induced by nickel chloride (NiCl2). Int J Mol
Sci. 16:22989–23011. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang X, Zheng D, Hu P, Zeng Z, Li M,
Tucker L, Monahan R, Resnick MB, Liu M and Ramratnam B: Glycogen
synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the
β-Catenin/TCF/LEF-1 pathway in gastric cancer cells. Nucleic Acids
Res. 42:2988–2998. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chu Q, Xu H, Gao M, Guan X, Liu H, Deng S,
Huo X, Liu K, Tian Y and Ma X: Liver-targeting Resibufogenin-loaded
poly(lactic-co-glycolic acid)-D-α-tocopheryl polyethylene glycol
1000 succinate nanoparticles for liver cancer therapy. Int J
Nanomedicine. 11:449–463. 2016.PubMed/NCBI
|
|
11
|
Xin XL, Sun JH, Wang XB, Xi RG, Wang G,
Lan R, Su DH, Li H, Huo XK and Wang C: Microbial transformation of
resibufogenin by Curvularia lunata AS 3.4381. J Asian Nat Prod Res.
16:290–295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mou LY, Xin XL, Chen L, Dong PP, Lan R, Su
DH, Huang J, Wang JH and Zhan LB: Biotransformation of
resibufogenin by Actinomucor elegans. J Asian Nat Prod Res.
16:623–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu J, Fu XQ, Zhou W, Yu HG, Yu JP and Luo
HS: LY294002 potentiates the anti-cancer effect of oxaliplatin for
gastric cancer via death receptor pathway. World J Gastroenterol.
17:181–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao J, Chen Y, Li W, Gong J, Zhou Z, Deng
Y, Wang L, Ren D, Wang J, Peng J and Lan P: Dose-dense biweekly
docetaxel combined with 5-fluorouracil as first-line treatment in
advanced gastric cancer: A phase II trial. Med Oncol. 32:3342015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi D, Bao YS and Liu YP:
Individualization of metal stents for management of gastric outlet
obstruction caused by distal stomach cancer: A prospective study.
Gastrointest Endosc. 78:277–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ichikawa M, Sowa Y, Iizumi Y, Aono Y and
Sakai T: Resibufogenin induces G1-phase arrest through the
proteasomal degradation of cyclin D1 in human malignant tumor
cells. PLoS One. 10:e01298512015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dolatkhah H, Movahedian A, Somi MH, Aghaei
M, Samadi N, Mirza-Aghazade A and Esfahani A: Effect of PUFAs oral
administration on the amount of apoptotic caspases enzymes in
gastric cancer patients undergoing chemotherapy. Anticancer Agents
Med Chem. 17:93–101. 2017.PubMed/NCBI
|
|
18
|
Frejlich E, Rudno-Rudzińska J, Janiszewski
K, Salomon L, Kotulski K, Pelzer O, Grzebieniak Z, Tarnawa R and
Kielan W: Caspases and their role in gastric cancer. Adv Clin Exp
Med. 22:593–602. 2013.PubMed/NCBI
|
|
19
|
Su CC and Chiu TL: Tanshinone IIA
decreases the protein expression of EGFR, and IGFR blocking the
PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro
and in vivo. Oncol Rep. 36:1173–1179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tapia O, Riquelme I, Leal P, Sandoval A,
Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P and
Roa JC: The PI3K/AKT/mTOR pathway is activated in gastric cancer
with potential prognostic and predictive significance. Virchows
Arch. 465:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fu Z, Yang J, Wei Y and Li J: Effects of
piceatannol and pterostilbene against β-amyloid-induced apoptosis
on the PI3K/Akt/Bad signaling pathway in PC12 cells. Food Funct.
7:1014–1023. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xing X, Zhang L, Wen X, Wang X, Cheng X,
Du H, Hu Y, Li L, Dong B, Li Z and Ji J: PP242 suppresses cell
proliferation, metastasis, and angiogenesis of gastric cancer
through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs.
25:1129–1140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen X, Liu Z, Cao BB, Qiu YH and Peng YP:
TGF-β1 neuroprotection via inhibition of microglial activation in a
rat model of parkinson's disease. J Neuroimmune Pharmacol.
12:433–446. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kanninen KM and White AR: Type-I
interferons in Parkinson's disease: Innate inflammatory response
drives fate of neurons in model of degenerative brain disorder: An
editorial comment on ‘Type-I interferons mediate the
neuroinflammatory response and neurotoxicity induced by rotenone’.
J Neurochem. 141:9–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang DL, Qi FH, Xu HL, Inagaki Y, Orihara
Y, Sekimizu K, Kokudo N, Wang FS and Tang W: Apoptosis-inducing
activity of compounds screened and characterized from cinobufacini
by bioassay-guided isolation. Mol Med Rep. 3:717–722.
2010.PubMed/NCBI
|
|
26
|
Wang L, Yin J, Wang X, Shao M, Duan F, Wu
W, Peng P, Jin J, Tang Y, Ruan Y, et al: C-type lectin-like
receptor 2 suppresses AKT signaling and invasive activities of
gastric cancer cells by blocking expression of phosphoinositide
3-kinase subunits. Gastroenterology. 150:1183–1195.e16. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cho YJ, Kim JH, Yoon J, Cho SJ, Ko YS,
Park JW, Lee HS, Lee HE, Kim WH and Lee BL: Constitutive activation
of glycogen synthase kinase-3beta correlates with better prognosis
and cyclin-dependent kinase inhibitors in human gastric cancer. BMC
Gastroenterol. 10:912010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Z, Cui J, Yu Q, Wu X, Pan A and Li L:
Evaluation of CCND1 amplification and CyclinD1 expression: Diffuse
and strong staining of CyclinD1 could have same predictive roles as
CCND1 amplification in ER positive breast cancers. Am J Transl Res.
8:142–153. 2016.PubMed/NCBI
|
|
29
|
Seiler R, Thalmann GN, Rotzer D, Perren A
and Fleischmann A: CCND1/CyclinD1 status in metastasizing bladder
cancer: A prognosticator and predictor of chemotherapeutic
response. Mod Pathol. 27:87–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Neal JT, Peterson TS, Kent ML and
Guillemin K: H. pylori virulence factor CagA increases intestinal
cell proliferation by Wnt pathway activation in a transgenic
zebrafish model. Dis Model Mech. 6:802–810. 2013. View Article : Google Scholar : PubMed/NCBI
|
